Trials / Unknown
UnknownNCT01373736
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Vancouver Coastal Health · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 123I-meta-iodobenzylguanidine |
Timeline
- First posted
- 2011-06-15
- Last updated
- 2011-06-15
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01373736. Inclusion in this directory is not an endorsement.